Immatics Nv (IMTX)

Shares of Immatics N.V. (NASDAQ:IMTX – Get Free Report) have been assigned an average rating of “Buy” from the five analysts that are presently covering the company, MarketBeat reports. Four equities… [+3551 chars]...

Shares of Immatics (NASDAQ:IMTX – Get Free Report) have earned an average recommendation of “Buy” from the five analysts that are currently covering the firm, MarketBeat.com reports. Four research an… [+3686 chars]...

Millennium Management LLC raised its position in Immatics (NASDAQ:IMTX – Free Report) by 379.2% in the fourth quarter, HoldingsChannel.com reports. The fund owned 156,686 shares of the company’s stoc… [+4041 chars]...

• Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity w… [+14845 chars]...
  Read more

Equities researchers at Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immatics (NASDAQ:IMTX – Get Free Report) in a research report issued to clients and investors on Wednesday, Mark… [+3972 chars]...